As of 2026-01-07, the Intrinsic Value of Royalty Pharma PLC (RPRX) is 39.89 USD. This RPRX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 40.65 USD, the upside of Royalty Pharma PLC is -1.90%.
The range of the Intrinsic Value is 18.03 - 188.15 USD
Based on its market price of 40.65 USD and our intrinsic valuation, Royalty Pharma PLC (RPRX) is overvalued by 1.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 18.03 - 188.15 | 39.89 | -1.9% |
| DCF (Growth 10y) | 19.34 - 178.66 | 39.94 | -1.7% |
| DCF (EBITDA 5y) | 70.34 - 86.94 | 79.21 | 94.9% |
| DCF (EBITDA 10y) | 69.86 - 94.77 | 82.35 | 102.6% |
| Fair Value | 33.13 - 33.13 | 33.13 | -18.50% |
| P/E | 24.94 - 39.68 | 32.13 | -20.9% |
| EV/EBITDA | 26.95 - 86.05 | 55.67 | 36.9% |
| EPV | (29.49) - (35.11) | (32.30) | -179.5% |
| DDM - Stable | 16.43 - 73.07 | 44.75 | 10.1% |
| DDM - Multi | 27.80 - 91.06 | 42.00 | 3.3% |
| Market Cap (mil) | 23,464.81 |
| Beta | 0.26 |
| Outstanding shares (mil) | 577.24 |
| Enterprise Value (mil) | 31,471.60 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.64% |
| Cost of Debt | 5.50% |
| WACC | 6.72% |